NASDAQ · Health care

Compass Therapeutics, Inc. (CMPX)

It posted a net loss of $86.4M. In fiscal 2025 capital spending exceeded operating cash flow by $49.2M. At September 30, 2026 it held $41.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.

Watch CMPX in 60 seconds

Price

$0.84

+10.29% on the day · November 9, 2026

52-week range $0.67 to $6.88

Market cap

$150.7M

Key facts about Compass Therapeutics, Inc.

Net worth: Compass Therapeutics, Inc. has a market value (market cap) of $150.7M at the latest share price, and shareholders' equity of $142.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $66.5M.
Cash flow: In fiscal 2025 operations used $49.1M of cash.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
Next earnings report: Compass Therapeutics, Inc.'s next report is expected around January 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

What Compass Therapeutics, Inc. does

Compass Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CMPX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$0	-$72.8M	-$66.5M	-$0.42	-$49.2M
2024	$850K	-$56.6M	-$49.4M	-$0.36	-$44.9M
2023	$0	-$50.4M	-$42.5M	-$0.33	-$40.6M
2022	n/a	-$41.7M	-$39.2M	-$0.37	-$34.3M
2021	n/a	-$81.9M	-$82.2M	-$1.31	-$21.2M
2020	n/a	-$27.8M	-$29.5M	-$0.96	-$26.9M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around January 5, 2027.

Estimated from its filing rhythm: 52 weeks after its report of January 6, 2026. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Latest SEC filings

What Compass Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

November 9, 2026
Quarterly report 10-Q · period to September 30, 2026Diluted EPS -$0.15 versus -$0.08.
November 9, 2026
Quarterly results 8-K
September 22, 2026
Investor disclosure 8-K
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 7, 2026
Passive stake (5% or more) SCHEDULE 13G
August 6, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.13 versus -$0.14.
August 6, 2026
Quarterly results 8-K
July 1, 2026
Investor disclosure 8-K
June 23, 2026
Bylaws or fiscal year changed 8-K
June 11, 2026
Shareholder vote results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on October 2, 2026. Insider transactions on SEC

Insider trades

What the people running Compass Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $21.3K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)

$21.3K

last 90 days

Sold

last 90 days

Net bought

22,500

$21.3K

Date	Insider	What	Shares	Price	Value	Filing
October 1, 2026	Lerner NeilChief Accounting Officer	Bought	20,000	$0.92	$18.4K	Form 4
September 24, 2026	Lerner NeilChief Accounting Officer	Bought	2,500	$1.14	$2.8K	Form 4
April 29, 2026	Anderman JonathanGeneral Counsel	Bought	25,000	$1.89	$47.3K	Form 4
April 29, 2026	Lerner NeilChief Accounting Officer	Bought	15,000	$1.89	$28.4K	Form 4
April 29, 2026	Lerner NeilChief Accounting Officer	Received as pay	15,000	$1.89	$28.4K	Form 4
April 29, 2026	Anderman JonathanGeneral Counsel	Received as pay	25,000	$1.89	$47.3K	Form 4
February 8, 2026	Schuetz Thomas J.CHIEF EXECUTIVE OFFICER, Director	Shares withheld for tax	36,687	$6.52	$239.2K	Form 4
January 9, 2026	Schuetz Thomas J.CHIEF EXECUTIVE OFFICER, Director	Shares withheld for tax	46,777	$5.35	$250.3K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns CMPX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Tang Capital Management, LLC13G, passive with 5 related filers	9.99%	17,176,510	November 14, 2025
Orbimed Advisors LLC13D, may seek influence with 1 related filers	8.9%	15,219,994	August 15, 2025
Suvretta Capital Management, LLC13G, passive with 2 related filers	8.2%	14,101,159	August 21, 2025

Latest filings below 5%: Vivo Opportunity Fund Holdings, L.P. 4% (August 14, 2026); Bvf Partners L P 4.3% (May 15, 2026); Blackstone Alternative Asset Management Associates LLC 3.4% (February 13, 2026); Commander Aggregator, LP 4.5% (August 18, 2025); RTW Investments, LP 0% (August 14, 2025).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 216 managers reported a position.

Holder	Shares	Value	Change on quarter
Tang Capital Management LLC	17,990,782	$39.4M	+1,199,973
Orbimed Advisors LLC	15,219,994	$33.3M	0
Montanova Capital, LLC	14,101,159	$30.9M	-206,220
BlackRock, Inc.	11,281,781	$24.7M	+1,775,701
State Street Corp	9,953,653	$21.8M	+3,258,677
Enavate Sciences GP, LLC	7,788,150	$17.1M	0
Vivo Capital, LLC	7,757,060	$17M	-1,788,406
Vanguard Capital Management LLC	6,118,782	$13.4M	+81,607
Palo Alto Investors LP	5,831,813	$12.8M	+4,317,309
Millennium Management LLC	4,713,247	$10.3M	+3,867,027
Geode Capital Management, LLC	3,815,189	$8.4M	+249,419
Vanguard Portfolio Management LLC	3,771,032	$8.3M	+2,688,381
Qube Research & Technologies Ltd	3,687,489	$8.1M	+1,137,133
Blue Owl Capital Holdings LP	3,624,076	$7.9M	+682,551
Citadel Advisors LLC	3,570,674	$7.8M	+2,849,264
Goldman Sachs Group Inc	3,531,000	$7.7M	+1,535,606
Rock Springs Capital Management LP	3,524,929	$7.7M	+219,621
Aqr Capital Management LLC	3,509,137	$7.7M	+3,308,709
Birchview Capital, LP	1,675,000	$3.7M	+209,133
Kingdon Capital Management, L.L.C.	1,400,000	$3.1M	new

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

4 insiders reported holding 7,744,336 shares in total, about $6.5M at the last price.

Holder	Shares	As of
Schuetz Thomas J.CHIEF EXECUTIVE OFFICER, Director	6,603,336	February 8, 2026
Shin BarryCFO	525,000	January 2, 2026
Lerner NeilChief Accounting Officer	420,000	October 1, 2026
Anderman JonathanGeneral Counsel	196,000	April 29, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CMPX

What does Compass Therapeutics, Inc. do?

Compass Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as CMPX. Its shares trade on NASDAQ under the ticker CMPX.

What is Compass Therapeutics, Inc.'s net worth?

Compass Therapeutics, Inc. has a market value (market cap) of $150.7M at the latest share price, and shareholders' equity of $142.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Compass Therapeutics, Inc. profitable?

No. Over the twelve months to September 30, 2026 it reported a net loss of $86.4M.

When did Compass Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.

When is Compass Therapeutics, Inc.'s next earnings report?

Compass Therapeutics, Inc.'s next report is expected around January 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

LENZ

LENZ Therapeutics, Inc.

HUMA

Humacyte, Inc.

TNYA

Tenaya Therapeutics, Inc.

OTLK

Outlook Therapeutics, Inc.

ARMP

Armata Pharmaceuticals, Inc.

CRBU

Caribou Biosciences, Inc.

Compare CMPX with

Compare CMPX with any company

Follow CMPX

Get an email when Compass Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values Compass Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.